lift trikafta vertex impress maintain hold
valuat
vertex report beat top line bottom line cystic
fibrosi cf non- revenu came revenu
includ adjust orkambi revenu vs consensu
sequenti non-gaap ep beat consensu vertex
end period cash
beat due rapid uptak newli launch trikafta
gener rest cf franchis came expect
kalydeco orkambi came consensu vs
vs respect symdeko revenu vs
expect strong start trikafta result surpris
tripl gener week launch inventori
conclus anoth solid quarter year vertex cf franchis
rapid uptak trikafta underpin continu domin
cf space vertex outlook cf franchis remain unchang
hold rate predic valuat
guidanc issu vertex issu guidanc revenu
vs actual non-gaap oper expens vs
actual reflect spend new program effect tax rate
updat model faster-than-expect launch
trikafta guidanc increas revenu estim
non-gaap ep estim increas
chang hold rate price target publish
uptak trikafta approv trikafta vertex ad het/min
patient age address market ultim vertex intend
expand younger patient trial expand patient age enrol
increas address market cf patient
patient cover kalydeco orkambi symdeko trikafta
approv see note link uptak progress rapidli
expect first month half launch drug gener
make compani success quarter singl cf product
note includ inventori channel vertex expect
modest growth rel
sickl cell diseas scd thalassemia tdt initi data gene
edit collabor crispr crsp nr trial underway
initi data patient posit tdt patient achiev neutrophil
engraft day platelet engraft day month
patient hemoglobin level g/dl scd patient free vaso-
occlus crise voc main target treatment month compar
baselin total hemoglobin level g/dl scd studi
enrol patient follow-up year tdt studi also enrol
year followup
collabor target condit regimen hcst
vertex enter collabor nr
up-front potenti royalti futur sale purpos agreement
develop target condit regimen could enhanc hcst process
includ compani gene edit therapi collabor employ
target engin toxin bodi platform specif target remov
cell enabl better engraft
condit hcst notori difficult reli larg chemotherapi
trial vertex use busulfan alreadi seen proof concept use
target therapi myeloabl condit actinium atnm buy apamistamab-
antibody-radiation-conjug platform acut myeloid leukemia boast
engraft rate on-going sierra trial
build beyond cf though expect cf growth continu note increas focu
pipelin activ includ acquisit exon duchenn
semma diabet collabor nr
hematopoet stem cell transplant hcst expect cash flow
continu build balanc sheet like focu go forward
antitrypsin defici compani two corrector
enrol data expect later expect patient
two mutat treat day chang blood level function
primari endpoint data on-going well
kidney diseas complet poc
plan evalu reduct protein level addit asset preclin
pain inhibitor program termin though compani
still portfolio asset plan advanc new molecul clinic
type diabet semma acquisit stem cell deriv islet sc-islet repres
potenti cur treatment type diabet advanc clinic trial expect
initi late
thousand except per share data
intang asset impair chang conting consider
relat activ
interest incom net
loss discontinu oper
net incom attribut vertex
compani report maxim group estim
